Advancing HER2-Low Breast Cancer Treatment

The Phase III DESTINY-Breast06 trial investigates Trastuzumab Deruxtecan (T-DXd) as a novel treatment for HER2-low breast cancer, a subtype with high unmet needs in HR-positive metastatic cases. Sponsored by AstraZeneca and Daiichi Sankyo, this multinational study aims to compare T-DXd against physician’s choice chemotherapy. It uses a randomised, parallel-group design and targets patients previously treated for HR+/HER2-low breast cancer. The primary endpoint is Progression-Free Survival...